<DOC>
	<DOCNO>NCT02006654</DOCNO>
	<brief_summary>To establish efficacy Lu AE58054 adjunctive therapy acetylcholinesterase inhibitor ( AChEIs ) symptomatic treatment patient mild-moderate Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>Lu AE58054 Patients With Mild Moderate Alzheimer 's Disease Treated With Acetylcholinesterase Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>The patient knowledgeable reliable caregiver . The patient outpatient . The patient probable AD . The patient mild moderate AD . Stable treatment AChEI . The patient , woman , must last natural menstruation â‰¥24 month prior baseline , OR surgically sterile . The patient , man , agree protocoldefined use effective contraception female partner childbearing potential , OR must surgically sterilise prior screen visit . The patient evidence clinically significant neurodegenerative disease , serious neurological disorder AD . The patient Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision ( DSMIVTR ) Axis I disorder AD . The patient evidence clinically significant disease . The patient 's current AChEI therapy likely interrupt discontinue study . The patient currently receive memantine take memantine within 2 month prior screen . Other inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>